Dechra Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Dechra Pharmaceuticals PLC
Public (LSEDPH)
Industry Pharmaceuticals
Founded 1997
Headquarters Northwich, United Kingdom
Key people
Michael Redmond, (Chairman)
Ian Page, (CEO)
Revenue £359.3 million (2017)[1]
£81.3 million (2017)[1]
£26.1 million (2017)[1]

Dechra Pharmaceuticals PLC is an England-based manufacturer of veterinary products. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.


The Company was founded in 1997 by way of a management buy-out from Lloyds Chemists.[2] It was first listed on the London Stock Exchange in 2000.[2] In 2007 it bought VetXX, a Danish veterinary products business, for £62m.[3] It sold its veterinary services business to US-firm, Patterson Companies, for £87.5m in July 2013 in order to focus on its higher margin manufacturing business.[4]


The Company sells pharmaceuticals - mainly for dogs, cats, equine and food producing animals; products include Vetoryl for Cushing's disease in dogs and Felimazole for hyperthyroidism in cats. It is organised into two divisions: European Pharmaceuticals and US Pharmaceuticals.[5]

See also


  1. ^ a b c "Annual Report 2017" (PDF). Retrieved 25 March 2018. 
  2. ^ a b Montague Private Equity announces sale of VetXX
  3. ^ "Dechra Pharma to buy VetXX for 61.7 mln stg". Reuters. Retrieved 28 March 2015. 
  4. ^ "Dechra sells up". Investors Chronicle. 11 July 2013. Retrieved 16 March 2014. 
  5. ^ "Dechra Pharmaceuticals PLC". Retrieved 28 March 2015. 

Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "Dechra Pharmaceuticals"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA